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Acute lung injury (ALI), instilled by lipopolysaccharide (LPS), is a severe illness with excessive mortality and has no speciﬁc
treatment strategy. Luteolin is an anti-inﬂammatory ﬂavonoid and widely distributed in the plants. Pretreatment with luteolin
inhibited LPS-induced histological changes of ALI and lung tissue edema. In addition, LPS-induced inﬂammatory responses,
including increased vascular permeability, tumor necrosis factor (TNF)-α and interleukin (IL)-6 production, and expression of
induciblenitricoxidesynthase(iNOS)andcyclooxygenase-2(COX-2),werealsoreducedbyluteolininaconcentration-dependent
manner. Furthermore, luteolin suppressed activation of NFκB and its upstream molecular factor, Akt. These results suggest that
the protection mechanism of luteolin is by inhibition of NFκB activation possibly via Akt.
1.Introduction
Lipopolysaccharide (LPS) as an endotoxin is the major com-
ponent of the outer wall membrane of Gram-negative bacte-
ria and exists in high concentration in tobacco and tobacco
smoke [1]. LPS is a potent trigger of septic shock and res-
piratory distress syndromes such as acute lung injury (ALI)
and its most severe presentation, acute respiratory distress
syndrome. However, ALI is not only strongly associated with
mortality in critically ill patients but also linked with a high
morbidity of approximately 34–58%. So far, no speciﬁc and
eﬀective treatment strategy for ALI has been established [2].
ThephysiologiccharacterizationsofALIarethatincrease
in alveolar-capillary permeability, plasma protein leakage,
protein-rich hyaline membrane formation, leukocytes inﬁl-
tration, pulmonary edema, and haemorrhaging [3, 4]. Pro-
inﬂammatory mediators such as tumor necrosis factor
(TNF)-α, interleukin (IL)-6, nitric oxide (NO), and prosta-
glandin E2 (PGE2) play a critical role in the process of
disease development in ALI [3]; while NO and PGE2 are
generated by inducible nitric oxide synthase (iNOS) and
cyclooxygenase (COX)-2, respectively, expression of TNF-
α, IL-6, iNOS, and COX-2 are regulated by transcription
factor, nuclear factor (NF)-κB, activation [5]. In addition,
protein kinase B (Akt/PKB), a serine/threonine kinase and
a major downstream factor of phosphoinositide 3-kinase
(PI3K), modulates NFκB activation in LPS-induced ALI [6].
Luteolin, a ﬂavonoid, is widely distributed in vegeta-
bles, fruits, and herbs. In traditional Chinese medicine,
plants rich in luteolin have been prescribed to treat
hypertension, inﬂammatory diseases, and cancer. Lute-
olin has been reported of expressing anti-inﬂammatory,
antioxidant, antiallergic, and antitumorigenic activities [7].
In macrophages, luteolin eﬀectively inhibits LPS-induced2 Evidence-Based Complementary and Alternative Medicine
proinﬂammatory cytokine expression and nitric oxide
production [8]. Moreover, luteolin signiﬁcantly reduces
PMN activation, involving superoxide anion generation,
leukotriene B4 secretion, migration, and chemotaxis [9,
10]. Recent study has shown that luteolin acts against
PMN activation via the mitogen-activated protein kinase
kinase/extracellular signal-regulated kinase (MEK/ERK) and
PI3K/Akt pathways [11]. The aim of this study is to
determinehowluteolinexertsitsanti-inﬂammatoryfunction
in ALI after LPS administration in in vivo animal model and
the mechanism involved.
2.MaterialsandMethods
2.1. Materials. Mouse polyclonal antibodies to glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) Akt, iNOS,
and COX-2 antibodies were obtained from Santa Cruz
Biotechnology. Rabbit polyclonal antibodies to phospho-Akt
were purchased from Cell Signaling Technology. Secondary
antibodies were obtained from Jackson ImmunoResearch.
Other chemicals were purchased from Sigma-Aldrich. The
ﬁnal volume of DMSO in the reaction mixture was <0.5%.
2.2. Animals. Adult healthy male ICR mice were purchased
from BioLASCO Taiwan (Taipei, Taiwan), weighing 25–30g.
The mice were maintained on a standard diet with tap
water ad libidum and housed in a 12h light/dark cycle in a
temperature-controlled environment (21 ± 1◦C). The ani-
mals were cared for in accordance with guidelines provided
by the Institutional Animal Ethics Committee of Chung
Shan Medical University and conducted in accordance with
the principles and guideline of the US National Institute of
Health Guide for the Care and Use of Laboratory Animals.
2.3. Murine Model of LPS-Induced Lung Inﬂammation. LPS-
induced ALI was performed as described in a previouse
study [11]. Seventy-ﬁve mice were randomly divided into 5
groups: sham operation group and four treatment groups.
The mice of the 4 treatment groups were injected with
0, 18, 35, or 70μmol/kg of luteolin intraperitoneally (I.P.)
for 30min, respectively, followed by intratracheal (I.T.)
instillation of LPS (100μg/50μL); the sham operation group
instead received vehicle I.P. for 30min then followed by
50μL of saline I.T. After 6 hours, the mice were sacriﬁced
by sodium pentobarbital, and samples were collected. In
each group, the right lung was collected from 5 animals for
histopathological studies, and the left lung for western blot
and NFκB activation assay. For the other 5 animals in each
group, Bronchoalveolar lavage ﬂuid (BALF) was collected
for TNF-α, IL-6, and protein concentration assay, and lung
samples for wet/dry weight ratio assay.
2.4. Lung Histopathological Studies. After midsternal thora-
cotomy, the mice underwent rapid excision of the lungs
which were ﬁxed via the trachea cannula with 4% isotonic
paraformaldehyde. The end of trachea was tie oﬀ,a n d
the whole lung was ﬁxed additionally in paraformaldehyde
for 24h then embedded in paraﬃna f t e rd e h y d r a t i o ni na
graded ethanol series and xylene. Serial sections of 3μmi n
thickness were performed using a rotatory microtome, and
the deparaﬃnized sections were stained with hematoxylin
and eosin. Evaluation of lung injury was performed under
the light microscope.
2.5. Lung Wet/Dry Weight Ratio. The ratios are representa-
tive of lung edema. The left lung was obtained and the wet
weight was recorded. The dry weight was determined after
the lung was baked in an incubator at 80◦Cf o r2 4h o u r sa n d
the wet/dry weight ratios were then calculated.
2.6. Protein Concentration in BALF. Bronchoalveolar lavage
was performed as previously described [11]. In short, after
euthanasia, trachea was exposed and intubated with a
tracheal cannula. Bronchoalveolar lavage was performed by
ﬂushing the airways and lungs repeatedly with 1mL cold
saline for three times. The pooled BALF was collected on ice
and centrifuged at 500g for 5min at 4◦C. Afterwards, the
supernatant was stored at −20◦C for further assay. Protein
concentrations in the cell-free BALF were determined using
Bio-Rad protein assay reagents. A standard curve was
generated in the same fashion using bovine serum albumin.
2.7. TNF-α and IL-6 Analysis. The levels of TNF-α and IL-
6 were measured on BALF using a commercially available
ELISA kit (R & D Systems, Minneapolis, Minn, USA). These
concentrations were interpolated from the standard curves
for recombinant TNF-α and IL-6.
2.8. Western Blot Analysis of Lung Tissue. The lungs were
harvested at 6h after LPS administration. After removing
extrapulmonary structures, lung tissue was frozen in liquid
nitrogen immediately until homogenization. Tissue extracts
were homogenized in tissue protein extraction solution (T-
PER; Pierce, Rockford, Ill, USA) containing 1% proteinase
inhibitor cocktail. After centrifugation, the protein con-
centration in the supernatant was determined by Bradford
assay [12]. Each well was loaded with 100μg of protein,
separated by SDS-PAGE, and electrophoretically transferred
to polyvinylidene diﬂuoride membrane. The membranes
were blocked with 5% (w/v) nonfat dried milk for 1h at
room temperature to reduce nonspeciﬁc binding, washed
with PBS containing 0.1% Tween-20 (PBST), then probed
with antibodies including iNOS, COX-2, GAPDH, and
phosphorylated and nonphosphorylated forms of Akt. After
the membranes were washed again with PBST, a 1:10,000
(v/v) dilution of horseradish peroxidase-labeled IgG was
added at room temperature for 1h, and the blots were
developed using ECL western blotting reagents.
2.9. NFκBA c t i v a t i o n .Nuclear extract from lung homo-
genates was measured by a nuclear extraction kit (NE-
PER Nuclear and Cytoplasmic Extraction Reagents, Thermo
Science) according to the manufacturer’s instructions, and
the protein concentration in the extract was determined
using a Bradford assay dye reagent (Bio-Rad). To detect
NFκB activation, a NFκB p65 Transcription Factor KitEvidence-Based Complementary and Alternative Medicine 3
(a) Control (b) LPS (c) 70 Luteolin + LPS (d) 35 Luteolin + LPS
(e) 18 Luteolin + LPS
Figure 1: Eﬀect of luteolin on LPS-induced histopathologic alterations in lung (400X). Histopathologic study of the lungs was performed
at the end of 6h right after LPS instillation. The lungs were removed immediately after the mice were sacriﬁced by thoracotomy, ﬁxed in
paraformaldehyde, embedded in paraﬃn, sectioned at 3μm, and stained with H&E before observation. (a) Vehicle-treated/LPS (−) group;
(b) vehicle-treated/LPS (+) group; (c) 70, (d) 35, and (e) 18μmol/kg luteolin-treated/LPS (+) group.
(Thermo Science) was used according to the manufacturer’s
instructions, in which 10μg of nuclear proteins were added
to the NFκB binding element coated 96-well plate for
1h, incubated with anti-p65 antibody, and followed by a
secondary antibody linked to horseradish peroxidase. Plates
were then developed with a chemiluminescent substrate and
read in a microplate reader.
2.10. Statistical Analysis. Statistical analyses were performed
using ANOVA followed by the Bonferroni t test for multi-
group comparisons; P<0.05 was considered signiﬁcant for
all tests.
3. Results
3.1. Eﬀects of Luteolin on LPS-Induced Histological Changes
in Lung. To evaluate the eﬀects of luteolin on ALI, we
examined the histological changes occurred in lung in LPS
administered mice with or without luteolin pretreatment.
Underlightmicroscope,theshamoperationgroupexpressed
normal lung structures and no damage was observed
(Figure 1(a)). As shown in Figure 1(b), administration of
LPS for 6h without luteolin pretreatment caused exten-
sive morphological damages in lung which were mani-
fested by increased in alveolar congestion, hemorrhage,
leukocytes inﬁltration into alveolar space, alveolar septum
thickness, and hyaline membrane formation (Figure 1(b)).
With 30min of luteolin pretreatment, we found that LPS-
induced histopathological damages were inhibited in a
concentration-dependentmanner(Figures1(c)–1(e)).These
results demonstrated that luteolin exerted protective eﬀect in
LPS-induced ALI mice.
3.2. Eﬀects of Luteolin on LPS-Induced Vascular Permeability
and Edema in Lung. The critical feature of LPS-induced ALI
is the destruction of vascular integrity, and the subsequent
upregulated permeability will result in protein leakage and
pulmonary edema [2]. Treatment with LPS alone was found
to signiﬁcantly increase protein leakage in BALF (P<0.05)
and edema in pulmonary parenchyma (P<0.05) in com-
parison with those of the sham operation group (Figure 2),
w h i l ew i t hp r e t r e a t m e n to fl u t e o l i na t3 5a n d7 0 μmol/kg
signiﬁcantly reduced protein leakage and pulmonary edema
(P<0.05). These results indicated luteolin prevented LPS-
induced pulmonary permeability and edema (Figure 2).
3.3. Eﬀects of Luteolin on LPS-Induced TNF-α and IL-
6 Production in BALF. TNF-α and IL-6 are important
mediatorsinrecruitmentofleukocytesintothelungsinLPS-
inducedALI[3,13].TheeﬀectofluteolinonTNF-αandIL-6
production in the BALF was analyzed by ELISA at the end of
6h LPS-treated period. Though LPS signiﬁcantly increased
the concentration of TNF-α a n dI L - 6w h e nc o m p a r e dw i t h
that of the control group (P<0.05), pretreatment of luteolin
at 70μmol/kg signiﬁcantly attenuated the production of
TNF-α and IL-6 (P<0.05, Figure 3). Furthermore, luteolin
reduced LPS-induced TNF-α and IL-6 production in a dose-
dependent manner.4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Eﬀect of luteolin on LPS-induced PMNs and protein accumulation in BALF. (a) PBS or 18–70μmol/kg of luteolin were
intraperitoneally injected for 30min prior to intratracheal instillation of LPS (100μg/50μL saline) or saline in mice. Six hours later, the
mice were anesthetized and BALF was collected for PMNs count. (b) Pulmonary permeability was determined by quantitating the protein
content in cell-free BALF. (c) Pulmonary edema was determined by quantitating the wet/dry weight ratio. Values are expressed as means ±
S.D. (n = 5 in each group). ∗P<0.05 versus control; #P<0.05 versus LPS group.
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Figure 3: Eﬀect of luteolin on LPS-induced TNF-α and IL-6 production in BALF. Values are expressed as means ± S.D. (n = 5i ne a c h
group). ∗P<0.05 versus control; #P<0.05 versus LPS group.
3.4. Eﬀects of Luteolin on LPS-Induced iNOS and COX-
2 Expressions. iNOS and COX-2 play critical roles in the
pathology of LPS-induced ALI [14, 15]. The eﬀect of luteolin
on iNOS and COX-2 expressions in lung tissue was analyzed
using a Western blot assay. The LPS signiﬁcantly increased
iNOS and COX-2 expressions compared with those of the
control group (P<0.05). Pretreatment with luteolin
reduced LPS-induced expressions of iNOS and COX-2 in a
concentration-dependent manner, both 35 and 70μmol/kg
signiﬁcantly attenuated the expression of the two proteins
(P<0.05) (Figure 4).
3.5. Eﬀects of Luteolin on LPS-Induced NFκBA c t i v a t i o n .
The activation of NFκB, which improves transcription of
most proinﬂammatory molecules, including TNF-α,I L - 6 ,
iNOS, and COX-2, has a pivotal role in ALI pathogenesis
[16]. To evaluate the eﬀects of luteolin on LPS-induced
NFκB activation in nuclear extracts from lung homogenates,
which were analyzed using NFκB p65 Transcription Factor
kit. The p65/p50 heterodimer is the most abundant NFκB
in LPS-induced toll-like receptor signaling [17]. Because
p50 lacks a transcriptional activation domain, we used
p65 as the indicator for NFκB activation. While the activ-
ity of NFκB increased markedly after LPS administration
when compared with that of the control group (P<
0.05), luteolin pretreatment reduced this activation in a
concentration-dependent manner with an IC50 value of
35.1 ± 15.8 μmol/kg. But a signiﬁcant inhibition of NFκBEvidence-Based Complementary and Alternative Medicine 5
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Figure 4: Eﬀect of luteolin on LPS-induced iNOS and COX-2 expression in lung. Lungs were harvested from posttreated mice and
whole tissue extracts were subjected to SDS-PAGE Western blot analysis using antibodies for iNOS, COX-2, and GAPDH. The ratio of
immunointensity between iNOS/GAPDH and COX-2/GAPDH was calculated. The fold increases in the immunointensity is expressed as
means ± S.D. (n = 3–5 in each group). ∗P<0.05 versus control; #P<0.05 versus LPS group.
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Figure 5: Eﬀect of luteolin on LPS-induced NFκB activation in
lung. Lungs were harvested from posttreated mice, and nuclear
extracts from whole lung tissues were analyzed by p65 transcription
FactorassaytostudytheactivationlevelsofNFκB.ThefoldofNFκB
activationbetweenthetreatmentandcontrolgroupswascalculated.
Values are expressed as means ± S.D. (n = 3–5 in each group).
∗P<0.05 versus control; #P<0.05 versus LPS group.
activation was only observed at 70μmol/kg (P<0.05)
(Figure 5).
3.6. Eﬀects of Luteolin on LPS-Induced Akt Activation. As
an upstream factor in NFκB activation, Akt participates
in LPS-induced ALI [6]. Phosphorylation on Akt S473
represents its maximal activation [18]. Therefore, the eﬀect
of luteolin on Akt activation in lung tissue was assessed
by phosphorylation of Akt at the site of S473 via western
blot analysis. Administration of LPS on mice signiﬁcantly
increased Akt phosphorylation compared with that of the
control group (P<0.05), and luteolin reduced LPS-induced
Akt phosphorylation in a concentration-dependent manner
with an IC50 value of 30.5 ± 17.8μmol/kg (Figure 6). These
results suggested that luteolin reduced the severity of LPS-
induced ALI via inhibition of the PI3K/Akt pathway.
4. Discussion
Experimental results obtained by this study demonstrated
that luteolin contributed to a preventive eﬀect on I.T. admin-
istration of LPS-induced inﬂammatory responses such as
alveolar congestion, haemorrhaging, leukocytes inﬁltration,
increase of alveolar wall thickness, protein leakage, and
edema in the lungs. We found the protection mechanism of
luteolin against LPS-induced ALI was via the suppression of
TNF-α and IL-6 productions, iNOS and COX-2 expressions,
and NFκB and Akt activation.
ALI is a clinical syndrome induced by multiple risk
factors and pathogens. Therefore, there is no ideal animal
model for ALI. The symptoms of LPS-induced ALI expresses
by the mouse model have close resemblance to the observed
pathology in human, even if the model cannot precisely
repeat all features of ALI [19]. LPS, an important virulent
macromolecule, consists of three regions: lipid A, which is
enclosed in the outer membrane; the core oligosaccharide,
which exists as a bridge between lipid A and O-antigen;6 Evidence-Based Complementary and Alternative Medicine
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Figure 6: Eﬀect of luteolin on LPS-induced Akt activation in
lung. Lungs were harvested from posttreated mice and whole tissue
extracts were subjected to SDS-PAGE Western blot analysis using
antibodies against phosphorylated and total Akt. The ratio of
immunointensity between the phosphorylation and total protein
was calculated. Values are expressed as means ± S.D. (n = 3–5 in
each group). ∗P<0.05 versus LPS group.
O-antigen, which is the outermost region. The toxic segment
of LPS is lipid A; core oligosaccharide and O-antigen are
the immunogenic but nontoxic portions. LPS is a primary
trigger for innate immunity and acute proinﬂammatory
responses. Therefore, LPS, a potent inducer of lung injury,
canbeemployedtoinvestigateALI.Toensurethatarealdose
is delivered to the lungs of each animal, LPS was adminis-
trated directly into the lungs via trachea [20]. Exposure to
LPS injures pulmonary vascular integrity, which is the most
importantinitialcauseofALI,resultsinhemorrhage,protein
leakage, and leukocytes inﬁltration in lung. These changes
contribute to the development of hyaline membrane and
congestion of alveolar spaces [21]. In addition, LPS increases
secretion of proinﬂammatory cytokines, including TNF-
α, IL-8, and IL-6, in alveolar macrophages and bronchial
epithelial cells [22, 23]. These proinﬂammatory cytokines
are crucial to leukocytes activation and recruitment into
the infected site [3]. Leukocytes activation produces reactive
oxygen species and protease that leads to alveolar barrier
disruption, permeability escalation, and direct tissue injury
[24]. Previous studies have demonstrated that pretreatment
with luteolin abolished the LPS-induced accumulation of
leukocytes in the air space [10, 11], and the in vitro
study has also demonstrated that luteolin can signiﬁcantly
lower formyl-Met-Leu-Phe-induced neutrophils chemotaxis
[11]. Oral administration of luteolin reduced bleomycin-
induced total cells and neutrophils proportion in BALF [25].
At present, we also found I.P. administration of luteolin
suppressed LPS-induced inﬂux of leukocytes into alveolar
space. Moreover, luteolin prevented alveolar congestion,
hemorrhage, increased in alveolar septal thickness, and
hyaline membrane formation caused by LPS. We also
demonstrated the ability of luteolin to inhibit LPS-induced
pulmonary permeability and edema. These results indicated
that luteolin might have beneﬁcial anti-inﬂammatory eﬀects
on animal model of LPS-induced ALI.
Proiinﬂammatory cytokines TNF-α and IL-6 not only
play critical roles but also contribute to the severity of lung
injury in ALI/ARDS patients [26]. The earliest and primary
endogenous mediator in the inﬂammatory process is TNF-
α, which primarily originates from alveolar macrophages.
The binding of TNF-α with receptors in lung tissue leads
to lysosomal leaking, directly resulting in the disruption of
pneumoangiogram vascular endothelial cells and increasing
their permeability. Moreover, TNF-α stimulates alveolar
epithelial cells to generate another proinﬂmmatory cytokine
such as IL-6[27]. Both TNF-α and IL-6 induce adhesion
molecule expression in vascular endothelial cells, result-
ing in recruitment of leukocytes into inﬂammatory site.
Therefore, TNF-α and IL-6 serve as predictive markers
for ALI severity. Many sequelae associated with ALI result
from persistent elevation of proinﬂammatory cytokines in
serum and BALF [28]. Previous studies have shown luteolin
inhibits LPS-induced TNF-α and IL-6 release from alveolar
macrophage [10, 29]. Studies done with mice model have
shown that bleomycin stimulated production of TNF-α and
IL-6 is reversed by luteolin [25]. Experimental data from
this study demonstrated that pretreatment with luteolin
downregulated expressions of TNF-α and IL-6 in the BALF
of mice been challenged with LPS for 6h afterwards. This
result implied that luteolin confers protection to mouse ALI
induced by LPS through reducing the production of TNF-α
and IL-6.
Expression of iNOS, which generates NO, and COX-
2, which generates prostaglandins and thromboxanes, con-
tributes to the pathophysiological progression of ALI [3, 30,
31]. In mouse alveolar macrophages, luteolin pretreatment
suppresses expression of iNOS and COX-2 after LPS admin-
istration [29]. An in vivo assay indicates that luteolin can
reverse the expression of iNOS and COX-2 if pretreated by
bleomycin [25]. According to our results, we concluded with
faircertaintythatluteolininhibitedLPS-inducedincreasesin
iNOS and COX-2 expressions in lung.
The expression of iNOS, COX-2, TNF-α, and IL-6 in
lung are regulated by NF-κB activation, which participates
in the regulation of the expression of multiple immediate
early genes involved in the acute inﬂammatory responses
[32, 33]. NF-κB activation is stimulated by LPS throughEvidence-Based Complementary and Alternative Medicine 7
activation of Akt [34], which is the major downstream
molecule of phosphoinositide 3-kinases. Its full activation
requires S473 phosphorylation in a hydrophobic motif [18].
Therefore,AktandPI3KparticipateinLPS-inducedALI[6].
LuteolinpreventsAktphosphorylationandNF-κBactivation
in LPS-stimulated alveolar macrophages [29]. In our present
study, the calculated IC50 values of luteolin obtained from
the inhibition of both Akt phosphorylation and NF-κB
activation are similar. These results suggested that luteolin
reduced the LPS-induced ALI by inhibiting NF-κBa ct i v a t i o n
probably via the PI3K/Akt pathway.
In conclusion, pretreatment with luteolin in the mouse
model markedly attenuated pulmonary inﬂammation in ALI
caused by LPS via I.T. administration. The manifestations
of pulmonary inﬂammation are as follows: (1) pathological
changes due to lung damage, such as increased in alveolar
congestion, hemorrhage, leukocytes inﬁltration into alveolar
space, alveolar septum thickness, and hyaline membrane for-
mation; (2) elevation of lung permeability and tissue edema;
(3) production of TNF-α and IL-6; (4) iNOS and COX-2
expressions in the lung. The molecular mechanism by which
luteolin protects the lung from injury is by inhibiting NF-κB
activation possibly via the PI3K/Akt pathway. Experimental
ﬁndings support the potential use of luteolin as a therapeutic
agent for prevention of ALI associated with direct infection
by Gram-negative bacteria.
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